Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Enliven Therapeutics (Nasdaq: ELVN) has commenced an underwritten public offering of $250 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $37.5 million of common shares, subject to market and other conditions.

Positive

• Proposed underwritten equity and warrant offering of $250 million
• 30-day underwriter option to purchase up to $37.5 million additional shares

Negative

• Completion, final size and terms of the offering are not assured

News Market Reaction – ELVN

+14.30% 3.9x vol

76 alerts

+14.30% Session close to close

+14.0% Peak Tracked

-8.3% Trough Tracked

$2.88B Market Cap

3.9x Rel. Volume

In the Jun 12 session, ELVN gained 14.30%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.0% during that session. Argus tracked a trough of -8.3% from its starting point during tracking. Our momentum scanner triggered 76 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.9x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +14.3% in the session following this news. A strong positive reaction aligns with h...

Analysis

The stock surged +14.3% in the session following this news. A strong positive reaction aligns with how Enliven’s stock has previously traded around financing news, where prior offering-tagged events averaged a +5.76% move. Investors have sometimes viewed capital raises as supportive for advancing late-stage programs. However, the proposed $250.0M deal and $37.5M underwriters’ option increase outstanding securities, which can later weigh on returns if enthusiasm fades.

Key Figures

Proposed offering size: $250.0 million Underwriters’ option: $37.5 million Option period: 30 days +2 more

5 metrics

Proposed offering size $250.0 million Underwritten public offering of common stock and pre-funded warrants

Underwriters’ option $37.5 million 30-day option for additional common stock

Option period 30 days Duration of underwriters’ option to purchase additional shares

Form S-3ASR date August 13, 2025 Registration Statement on Form S-3ASR became automatically effective

Announcement date June 11, 2026 Date of proposed public offering announcement

Previous Offering Reports

3 past events · Latest: Jun 16 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 16	Offering closed	Neutral	-5.6%	Closed prior equity offering with full underwriter option exercise and gross proceeds.
Jun 13	Offering priced	Neutral	+11.4%	Announced pricing of equity and pre-funded warrant offering with expected proceeds.
Jun 13	Offering proposed	Neutral	+11.4%	Proposed equity and pre-funded warrant raise with underwriter option disclosed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past equity offerings and related announcements have produced mixed but generally positive reactions, with an average move of +5.76% across three prior offering-tagged events.

Recent Company History

Over the past year, Enliven has repeatedly used public offerings of common stock and pre-funded warrants, with three offering-related announcements between Jun 13–16, 2025. Those deals raised roughly $200M–$230M in gross proceeds and involved underwriter options and warrant components similar to today’s structure. Price reactions ranged from -5.59% on the closing release to +11.44% on the proposed and pricing announcements, indicating historically volatile responses around financing news.

Key Terms

pre-funded warrants, underwritten public offering, registration statement on form s-3asr, base prospectus, +2 more

6 terms

pre-funded warrants financial

"in lieu of common stock to investors who so choose, pre-funded warrants to purchase"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"it has commenced an underwritten public offering of $250.0 million of shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

registration statement on form s-3asr regulatory

"The offering is being made pursuant to a Registration Statement on Form S-3ASR, including"

A registration statement on Form S-3ASR is a pre-approved filing used by well-established public companies to register securities they may sell over time, with the paperwork becoming effective automatically so offerings can begin quickly. For investors, it matters because it lets a company raise money or issue stock or debt on short notice — like a company keeping a ready-to-use credit line — which can dilute existing shares or change the company’s cash position rapidly.

base prospectus regulatory

"on Form S-3ASR, including a base prospectus, which became automatically effective"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

preliminary prospectus supplement regulatory

"Enliven will file a preliminary prospectus supplement and accompanying prospectus"

A preliminary prospectus supplement is an initial document that provides important details about a new stock or bond offering before it is finalized. It helps investors understand what is being sold and why, so they can decide whether to invest. Think of it as a preview before the full sales brochure is ready.

book-running managers financial

"Goldman Sachs & Co. LLC, Morgan Stanley and Barclays are acting as joint book-running managers"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley and Barclays are acting as joint book-running managers for the proposed offering. Mizuho is also acting as a book-running manager and LifeSci Capital is acting as a passive book-running manager for the proposed offering.

The offering is being made pursuant to a Registration Statement on Form S-3ASR, including a base prospectus, which became automatically effective upon filing with the U.S. Securities and Exchange Commission (SEC) on August 13, 2025, and Enliven will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which can be accessed for free through the SEC's website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Enliven within the meaning of the federal securities laws, including those related to the completion, timing, and size of the offering and Enliven's intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not Enliven will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Enliven files from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the public offering. These forward-looking statements are made as of the date of this press release, and Enliven assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302798527.html

SOURCE Enliven Therapeutics, Inc.

FAQ

What did Enliven Therapeutics (Nasdaq: ELVN) announce on June 11, 2026 about a stock offering?

Enliven Therapeutics announced it has commenced an underwritten public offering of $250 million in common stock and pre-funded warrants. According to Enliven, all securities are offered by the company, with completion subject to market and other conditions.

How large is the proposed Enliven Therapeutics (ELVN) common stock and pre-funded warrants offering?

The proposed offering totals $250 million of common stock and pre-funded warrants. According to Enliven, the company may also grant underwriters a 30-day option to purchase up to an additional $37.5 million of common shares, depending on market conditions.

What is the 30-day underwriter option in the Enliven Therapeutics (ELVN) June 2026 offering?

Enliven plans to grant underwriters a 30-day option to buy up to $37.5 million of additional common shares. According to Enliven, this option would be in addition to the initial $250 million offering of common stock and pre-funded warrants.

Who are the book-running managers for the Enliven Therapeutics (ELVN) June 2026 offering?

Jefferies, Goldman Sachs, Morgan Stanley and Barclays are joint book-running managers, with Mizuho also a book-running manager. According to Enliven, LifeSci Capital will act as a passive book-running manager for the proposed common stock and pre-funded warrants offering.

How can investors access the preliminary prospectus for the Enliven Therapeutics (ELVN) stock offering?

Investors can access the preliminary prospectus supplement and prospectus for free via the SEC’s website at www.sec.gov. According to Enliven, copies will also be available from Jefferies, Goldman Sachs, Morgan Stanley, or Barclays through their listed postal, phone, or email contacts.

Is the Enliven Therapeutics (ELVN) public offering guaranteed to be completed as announced?

The offering is not guaranteed to be completed as announced. According to Enliven, completion, timing, actual size and terms of the offering are subject to market and other conditions, and there can be no assurance it will be finalized.